Across TCGA pan-cancer cohorts, IGHD3-3 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGHD3-3’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where IGHD3-3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHD3-3 is over-expressed in tumor, although a few such as READ show the opposite, repressed pattern.
LUAD, HNSC, and KIRC are the cancer types where IGHD3-3 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD3-3 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.